Thirty-one intensively pretreated children with ALL in first bone marrow relapse or refractory to initial therapy were treated with a combination of intermediate-dose Ara-C and idarubicin (IDA). Twenty-four patients (77%) achieved complete remission (CR), 8 patients relapsed early and 2 were removed from the study. Fourteen (45% of the original 31 patients) underwent bone marrow transplant (BMT) and 7 of them (22%) are still in continuous CR (CCR) with a median follow-up of 18 months. These results confirm that it is possible to achieve CR even in ALL children who failed on an initial intensive regimen. Newer modalities of post-remission therapy, especially for children lacking an HLA donor, should be considered
Reinduction therapy in children with primary refractory or relapsed acute lymphoblastic leukemia / Testi, Anna Maria; Moleti, Ml; Giona, Fiorina; Iori, Ap; Meloni, Giovanna; Miniero, R; Pigna, M; Amadori, S; Mandelli, Franco. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 3:(1992), pp. 765-767.
Reinduction therapy in children with primary refractory or relapsed acute lymphoblastic leukemia
TESTI, Anna Maria;GIONA, Fiorina;MELONI, Giovanna;MANDELLI, Franco
1992
Abstract
Thirty-one intensively pretreated children with ALL in first bone marrow relapse or refractory to initial therapy were treated with a combination of intermediate-dose Ara-C and idarubicin (IDA). Twenty-four patients (77%) achieved complete remission (CR), 8 patients relapsed early and 2 were removed from the study. Fourteen (45% of the original 31 patients) underwent bone marrow transplant (BMT) and 7 of them (22%) are still in continuous CR (CCR) with a median follow-up of 18 months. These results confirm that it is possible to achieve CR even in ALL children who failed on an initial intensive regimen. Newer modalities of post-remission therapy, especially for children lacking an HLA donor, should be consideredI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.